Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes

被引：0

作者：

Andre, V. ^{[1
]}

Harbeck, N. ^{[2
]}

Rastogi, P. ^{[3
,4
]}

O'Shaughnessy, J. ^{[5
]}

Boyle, F. ^{[6
]}

Cortes, J.

Rugo, H. S. ^{[7
,8
]}

Goetz, M. P. ^{[9
]}

Hamilton, E. ^{[10
]}

Huang, C. -s.

Senkus, E. ^{[11
]}

Tryakin, A. ^{[12
]}

Neven, P. ^{[13
]}

Huober, J. ^{[14
]}

Wei, R. ^{[1
]}

Munoz, M. ^{[1
]}

Antonio, B. S. ^{[1
]}

Shahir, A. ^{[1
]}

Martin, M. ^{[15
]}

Johnston, S. ^{[16
]}

机构：

[1] Eli Lilly & Co, Indianapolis, IN USA

[2] LMU Univ Hosp, Breast Ctr, Comprehens Canc Ctr Munchen, Dept Gynecol & Obstet, Munich, Germany

[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[4] NSABP Fdn, Pittsburgh, PA USA

[5] Baylor Univ, Texas Oncol, US Oncol, Med Ctr, Dallas, TX USA

[6] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia

[7] Int Breast Canc Ctr IBCC, Quironsalud Grp, Barcelona, Spain

[8] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, San Francisco, CA USA

[9] Mayo Clin, Rochester, MN USA

[10] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA

[11] Med Univ Gdansk, Gdansk, Poland

[12] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[13] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Louvain, Belgium

[14] Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland

[15] Univ Complutense, Hosp Gen Univ Gregorio Maranon, CIBERONC, GEICAM, Madrid, Spain

[16] Royal Marsden NHS Fdn Trust, London, England

来源：

BREAST | 2025年 / 80卷

关键词：

D O I：

10.1016/j.breast.2025.103903

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P009

引用

页数：2

共 50 条

[31] Primary Outcome Analysis of Invasive Disease-Free Survival for MonarchE: Abemaciclib Combined With Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
O'Shaughnessy, Joyce A.
Johnston, Stephen
Harbeck, Nadia
Toi, Masakazu
Im, Young-Hyuck
Reinisch, Mattea
Shao, Zhimin
Lehtinen, Pirkko Liisa Kellokumpu
Huang, Chiun-Sheng
Tryakin, Alexey
Goetz, Matthew
Rugo, Hope S.
Senkus, Elzbieta
Testa, Laura
Andersson, Michael
Tamura, Kenji
Steger, Guenther G.
Del Mastro, Lucia
Cox, Joanne
Forrester, Tammy
Sherwood, Sarah
Li, Xuelin
Wei, Ran
Martin, Miguel
Rastogi, Priya
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 15 - 16
[32] Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Johnston, Stephen R. D.
Toi, Masakazu
O'Shaughnessy, Joyce
Rastogi, Priya
Campone, Mario
Neven, Patrick
Huang, Chiun-Sheng
Huober, Jens
Jaliffe, Georgina Garnica
Cicin, Irfan
Tolaney, Sara M.
Goetz, Matthew P.
Rugo, Hope S.
Senkus, Elzbieta
Testa, Laura
Del Mastro, Lucia
Shimizu, Chikako
Wei, Ran
Shahir, Ashwin
Munoz, Maria
San Antonio, Belen
Andre, Valerie
Harbeck, Nadia
Martin, Miguel
LANCET ONCOLOGY, 2023, 24 (01): : 77 - 90
[33] Abemaciclib Improves Disease-Free Survival in High-Risk HR+/HER2-Early Breast Cancer
不详
ONCOLOGIST, 2021, 26 : S5 - S6
[34] Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2-high-risk breast cancer
Sammons, Sarah
Moore, Heather
Cushman, Jaycee
Hamilton, Erika
EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 805 - 814
[35] eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
Tolaney, Sara M.
Fallowfield, Lesley
Kaufman, Peter A.
Ciruelos, Eva M.
Gainford, Mary Corona
Lu, Yi
Hurt, Karla
Wasserstrom, Heather Ann
Chen, Yanyun
Goel, Shom
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[36] Adjuvant Therapy of HR+, HER2 Breast Cancer Prolonging Survival without invasive Disease in high-risk early Breast Cancer
Ruedesheim, Sabine M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8)
[37] Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'
Harbeck, N.
Rastogi, P.
Shahir, A.
Johnston, S.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2022, 33 (02) : 227 - 228
[38] Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
Turner, Nicholas
Reis-Filho, Jorge
Goetz, Matthew
Desmedt, Christine
Chandarlapaty, Sarat
Sasano, Hironobu
Arteaga, Carlos
Loi, Sherene
Graff, Stephanie
Liu, Deli
Rodrik-Outmezguine, Vanessa
Sireci, Anthony
Rubenstein, Cynthia Sandoval
Won, Helen
Litchfield, Lacey M.
Munoz, Maria
Johnston, Stephen
CANCER RESEARCH, 2024, 84 (09)
[39] MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2-advanced breast cancer - Results from the preplanned final PFS analysis
Goetz, Matthew P.
Martin, Miguel
Di Leo, Angelo
Im, Seock-Ah
Awada, Ahmad
Forrester, Tammy
Frenzel, Martin
Cox, Joanne
Barriga, Susana
Toi, Masakazu
Iwata, Hiroji
Johnston, Stephen
CANCER RESEARCH, 2018, 78 (13)
[40] Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer
O'Shaughnessy, Joyce A.
Johnston, Stephen
Harbeck, Nadia
Toi, Masakazu
Im, Young-Hyuck
Reinisch, Mattea
Shao, Zhimin
Lehtinen, Pirkko Liisa Kellokumpu
Huang, Chiun-Sheng
Tryakin, Alexey
Goetz, Matthew
Rugo, Hope S.
Senkus, Elzbieta
Testa, Laura
Andersson, Michael
Tamura, Kenji
Steger, Guenther G.
Del Mastro, Lucia
Cox, Joanne
Forrester, Tammy
Sherwood, Sarah
Li, Xuelin
Wei, Ran
Martin, Miguel
Rastogi, Priya
CANCER RESEARCH, 2021, 81 (04)

← 1 2 3 4 5 →